Abstract: This invention relates to compositions and methods for the detection of HIV-1 antibodies employing polypeptides obtained from the Gag-p6 protein, the method comprising the steps of: (a) contacting a biological sample with a peptide having an epitope that is recognized by the anti-HIV-1 antibody where the contacting is under conditions sufficient to permit anti-HIV-1 present in the sample to bind to the epitope and form a peptide-anti-HIV-1 antibody complex; (b) contacting the formed peptide-anti-HIV-1 antibody complex with an anti-HIV-1 antibody binding molecule under conditions sufficient to permit the anti-HIV-1 antibody binding molecule to bind to anti-HIV-1 antibody of the formed peptide-anti-HIV-1 antibody complex and form an extended complex; said extended complex being immobilized on a solid support; and (c) removing unbound antibody from said extended complex; and (d) determining the presence or concentration of the anti-HIV-1 antibody in the biological sample by determining the presence or concentrat

Abstract: Peptides and polypeptides that elicit immunogenic responses in a mammal; especially neutralizing antibodies, against human and avian influenza strains H1N1, H3N2, H5N1 and H7N7 are disclosed Immunogenic compositions including these peptides, and polypeptides are also provided. Compositions including these peptides and polypeptides with or without adjuvants are disclosed. Nucleic acids and expression cassettes encoding these peptides and polypeptides are also disclosed. Methods of inhibiting infection by influenza, with or without cell entry, are also disclosed using these peptides and polypeptides.

Abstract: The present invention relates, e.g., to an isolated peptide comprising a sequence of contiguous amino acids that is at least about 60% identical (e.g., at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 100% identical) to the sequence E-W-Q-K-E-G-L-V-T-L-W-L (SEQ ID NO:1), or an active variant of an isolated peptide comprising SEQ ID NO:1. Neutralizing antibodies generated by, or specific for, such peptides are also described, in particular antibodies which are specific for the HIV co-receptor, CCR5, and which inhibit infection of a host cell by HIV. Neutralizing single strand and complete human monoclonal antibodies against CCR5 are described. Methods of using such peptides or antibodies, for inhibiting infection by HIV, are also described.

Abstract: The present invention relates, e.g., to an isolated peptide comprising a sequence of contiguous amino acids that is at least about 60% identical (e.g., at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 100% identical) to the sequence E-W-Q-K-E-G-L-V-T-L-W-L (SEQ ID NO:1), or an active variant of an isolated peptide comprising SEQ ID NO:1. Neutralizing antibodies generated by, or specific for, such peptides are also described, in particular antibodies which are specific for the HIV co-receptor, CCR5, and which inhibit infection of a host cell by HIV. Neutralizing single strand and complete human monoclonal antibodies against CCR5 are described. Methods of using such peptides or antibodies, for inhibiting infection by HIV, are also described.

Abstract: The instant invention relates to methods for treating a subject suffering from or susceptible to an autoimmune disease or disorder, or a disease or disorder having an autoimmune component, comprising administering to the subject an effective amount of cyclophilin or a biologically active fragment thereof.

Abstract: This invention relates to compositions and methods or the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.

Abstract: The present invention relates, e.g., to an isolated peptide comprising a sequence of contiguous amino acids that is at least about 60% identical (e.g., at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 100% identical) to the sequence E-W-Q-K-E-G-L-V-T-L-W-L (SEQ ID NO:1), or an active variant of an isolated peptide comprising SEQ ID NO:1. Neutralizing antibodies generated by, or specific for, such peptides are also described, in particular antibodies which are specific for the HIV co-receptor, CCR5, and which inhibit infection of a host cell by HIV. Neutralizing single strand and complete human monoclonal antibodies against CCR5 are described. Methods of using such peptides or antibodies, for inhibiting infection by HIV, are also described.

Abstract: The present invention provides a rapid method to determine invasion of a cell by an invasion.

Abstract: The instant invention relates to methods for treating a subject suffering from or susceptible to an autoimmune disease or disorder, or a disease or disorder having an autoimmune component, comprising administering to the subject an effective amount of cyclophilin or a biologically active fragment thereof.